Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy

MT-LOOP-dependent Localization of Membrane Type I Matrix Metalloproteinase (MT1-MMP) to the Cell Adhesion Complexes Promotes Cancer Cell Invasion

(2013) Anna M. Woskowicz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1–MMP

(2013) S A Shiryaev et al.   Oncogenesis

ADAM-17: a novel therapeutic target for triple negative breast cancer

(2012) P. M. McGowan et al.   ANNALS OF ONCOLOGY

Rezymogenation of active urokinase induced by an inhibitory antibody

(2012) Longguang Jiang et al.   BIOCHEMICAL JOURNAL

EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

(2012) Christine M. Ardito et al.   CANCER CELL

Improvements to the Kunkel mutagenesis protocol for constructing primary and secondary phage-display libraries

(2012) Renhua Huang et al.   METHODS

Primer Extension Mutagenesis Powered by Selective Rolling Circle Amplification

(2012) Tuomas Huovinen et al.   PLoS One

Anti-Tumour Effects of a Specific Anti-ADAM17 Antibody in an Ovarian Cancer Model In Vivo

(2012) Frances M. Richards et al.   PLoS One

Cross-domain inhibition of TACE ectodomain

(2011) C. J. Tape et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tissue inhibitors of metalloproteinases

(2011) Gillian Murphy   GENOME BIOLOGY

Thiol isomerases negatively regulate the cellular shedding activity of ADAM17

(2010) Sofie H. Willems et al.   BIOCHEMICAL JOURNAL

Oncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17

(2010) S. Van Schaeybroeck et al.   CANCER RESEARCH

Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer

(2010) Fusanori Yotsumoto et al.   CANCER SCIENCE

Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

(2010) J. N. Kyula et al.   CLINICAL CANCER RESEARCH

ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site

(2010) S. M. Le Gall et al.   JOURNAL OF CELL SCIENCE

Therapeutic antibody targeting of individual Notch receptors

(2010) Yan Wu et al.   NATURE

ADAM17 as a Therapeutic Target in Multiple Diseases

(2009) Joaquin Arribas et al.   CURRENT PHARMACEUTICAL DESIGN

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Specific targeting of metzincin family members with small-molecule inhibitors: Progress toward a multifarious challenge

(2008) Dimitris Georgiadis et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Current perspective of TACE inhibitors: A review

(2008) Shirshendu DasGupta et al.   BIOORGANIC & MEDICINAL CHEMISTRY

TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer

(2008) N. B. Merchant et al.   CLINICAL CANCER RESEARCH

The ADAM metalloproteinases

(2008) D EDWARDS et al.   MOLECULAR ASPECTS OF MEDICINE

Resistance to Chemotherapy in Cancer: A Complex and Integrated Cellular Response

(2008) Howard R. Mellor et al.   PHARMACOLOGY

Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases’

(2008) Gillian Murphy   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

(2008) Marcia L Moss et al.   Nature clinical practice. Rheumatology